1. Scrip
  2. >>Focus On Asia
  3. >>China

Watch Out Sanofi! Chinese Fast-Follower Emerges With Dupixent Rival

Promising Top-Line Data

 
• By Dexter Jie Yan

Keymed’s anti-IL-4Rα antibody stapokibart has delivered compelling top-line efficacy and safety results in a China Phase III study, which could help it challenge Sanofi/Regeneron’s Dupixent in the country.

fast followers
Keymed's stapokibart is closing in on Dupixent in the atopic dermatitis space in China • Source: Shutterstock

Stapokibart (CM310, a monoclonal antibody against interleukin-4 receptor alpha (IL-4Rα) from China-based biotech Keymed Biosciences Inc. , appears set to emerge as a rival to Sanofi/Regeneron Pharmaceuticals, Inc.’s Dupixent (dupilumab) in the country, backed by positive new top-line Phase III results in adult moderate-to-severe atopic dermatitis.

Key Takeaways

  • Top-line results from a Phase III trial of Keymed’s anti-IL-4Rα antibody stapokibart (CM310) in Chinese adults with moderate-to-severe atopic dermatitis were presented at the EADV congress in Berlin.

The outcomes from the 500-patient, China-only CM310AD005 trial, which is still ongoing, show an Investigator’s Global Assessment (IGA) score of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

More from Focus On Asia

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?